It depends on the standard you follow. As of September 2026, Avita Medical Inc. (RCEL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 11.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.47% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 11.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.66% / 33% · Receivables / Mkt Cap (36m) 2.63% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 11.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.66% / 33.33% · Receivables / Mkt Cap (24m) 2.63% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 90.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 26.7% / 33.33% · Receivables / Avg Assets (4Q) 19.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 97.2% / 33.33% · (Cash+ST Inv) / Total Assets 22.4% / 33.33% · (Cash+Recv) / Total Assets 44.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Avita Medical Inc. (RCEL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Avita Medical Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Avita Medical Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Avita Medical Inc. (NASDAQ: RCEL) is a Healthcare company (Medical - Devices) with a market capitalization of $392M. The Maz Rating grades it against the other companies in its sector.
Avita Medical Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.77, Avita Medical Inc. trades at 4.7x sales. Over the last twelve months it generated about $84M of revenue and a net loss of $29M. It runs a gross margin of 82.4%, an operating margin of -33.9% and a net margin of -42.6%. It shows return on equity of 146.4%, return on invested capital of -120.8% and a free cash flow yield of -4.7%. On the balance sheet: a debt-to-equity ratio of -1.52 and a current ratio of 1.20. Over the past 52 weeks the share price ranged from $3.22 to $18.43, with a beta of 2.01.
Avita Medical Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.